KCT0004166尚未招募未知
An Open-label, Parallel, Single-Dose, Clinical Study after administration of WS1313D in Children and Adolescent with Pain to Evaluate Pharmacokinetics (PK) / Pharmacodynamics (PD) and Safety
Woosung Pharma0 个研究点目标入组 62 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 2(Year) 至 19(Year)（—）
- 性别
- All
入选标准
- •The subjects to be enrolled in this study should satisfy all of the following criteria.
- •1) Age and weight: Children From about 2 years old to under 11 years old and weighing from 10 kg to less than 33 kg. Or adolescents who are between about 11 years old and under 19 years old and weigh more than 33 kg but less than 50 kg. However, age is only a reference item, and when the age and weight range do not match, the investigator will decide whether or not to select the weight based on the weight.
- •2) Admission status: Those who were admitted to the hospital from the time of screening, who are scheduled to be admitted during the clinical trial period, or who are scheduled to be admitted to the hospital on the scheduled date of administration of the clinical trial drug.
- •3) Disease: Those who are expected to need medication due to moderate pain.
- •4) IV: Severe nausea / nausea or vomiting symptoms that lead to an NPO (nothing by mouth). Or those who are expected to require IV administration due to scheduled surgery, such as those who need intravenous or rapid intravenous administration at the discretion of the investigator.
- •5) Those who can participate in the entire period of this clinical trial.
- •6) If the subject's volunteer voluntarily signs a written ICF(Informed Consent Form) to participate in the subject's clinical trial (including signature of the subject's participation in clinical trials if possible)
排除标准
- •The subjects to be enrolled in this trial are excluded if any of the following criteria are met.
- •1) Those who can not collect blood of up to 7 mL / kg per day required by this clinical trial.
- •2) Those who have hypersensitivity to the active ingredient or additive of the clinical trial drug.
- •3) Within 24 hours prior to administration of the clinical trial drug and within 12 hours of the screening time, the drug containing acetaminophen (acetaminophen or paracetamol) or propacetamol was administered, or the drug containing probenecid or isoniazide was administered within 48 hours If you have received medication containing disulfiram within one month
- •4) A patient with severe hepatic impairment or total bilirubin is measured at 1.5 times the normal upper limit of the clinical laboratory or the ALT or AST is 2.5 times the normal upper limit of the clinical laboratory.
- •5) Patients with severe renal impairment or eGFR (Estimated glomerular filtration rate) less than 1/3 of the normal lower limit of clinical laboratory.
- •6) For pregnant or lactating women, or as a child of childbearing age, medically accepted methods of contraception from the screening date of the trial to the 30th day after the last dose of the clinical trial drug, either not agreeing to use at least two of the following contraceptive methods, Those who disagree
- •- Medicines: Oral contraceptives, skin patches or progestins (implants or injections)
- •- Diaphragmatic method: condom, diaphragm, intrauterine device (IUD), vaginal suppository
- •- Abstinence: Absolute abstinence (except periodical abstinence (eg calendars, ovulation, symptom thermotherapy) and abstinence are not considered contraceptive methods.)
- •7) Those who participated in other clinical trials within 90 days of screening
- •8) Patients with peptic ulcer
- •9) Patients with severe blood disorders
- •10) Patients with severe hepatic impairment
- •11) Patients with severe renal impairment
- •12) Patients with severe cardiac dysfunction
- •13) Patients with aspirin asthma (asthma attacks caused by non-steroidal anti-inflammatory drugs)
- •14) Patients taking the following drugs: barbiturates, tricyclic antidepressants
- •15) Patients taking the drug within 48 hours after administration of the drug for clinical trial
- •16) Those who are diagnosed as not being able to participate in the clinical trial according to the judgment of the investigator
研究者
相似试验
已完成
不适用
A randomized, open-label, single dose, parallel study to evaluate the pharmacokinetics dose proportionality of GLA5PR GLARS-NF1 tablet in healthy male volunteersEndocrine, nutritional and metabolic diseaseKCT0001312GL PharmTech40
已完成
不适用
A randomized, open-label, single-dose parallel-group trial to determine the pharmacokinetics and safety of GP2017 following a single subcutaneous injection by an autoinjector or by a pre-filled syringe in healthy male subjectsautoimmune diseasesincluding rheumatoid arthritis and psoriasis10003816NL-OMON42002Hexal AG108
尚未招募
3 期
A clinical study to evaluate the the Anabolic Efficacy of PRP-02 in Healthy Human Adults.CTRI/2024/06/068758Amway Global Services India (AGSI)
进行中（未招募）
1 期
A clinical study of the level of drug (Ticagrelor) in blood in infants and toddlers, aged 0 to less than 24 months with Sickle Cell DiseaseSickle Cell DiseaseEUCTR2017-003641-14-GBAstraZeneca AB21
进行中（未招募）
1 期
A clinical study of the level of drug (Ticagrelor) in blood in infants and toddlers, aged 0 to less than 24 months with Sickle Cell DiseaseMedDRA version: 20.0 Level: LLT Classification code 10040644 Term: Sickle cell disease System Organ Class: 100000004850Sickle Cell DiseaseEUCTR2017-003641-14-ESAstraZeneca AB21